-

Denise Vitola Joins Bayer Communications Team

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health. In this role, Vitola will be responsible for leading strategy for integrated brand PR, social media and influencer marketing for all Consumer Health U.S. brands.

For the last two years, Vitola has played an integral role as a consultant leading internal communications and brand PR for Bayer Consumer Health North America, including spearheading the advancement of influencer marketing and organic social for Consumer Health North America and launching new integrated campaigns for Midol®, Bayer® Aspirin, AleveX™, One-A-Day®, Claritin® and Alka-Seltzer®.

Vitola will report to Beth Roden, SVP and Head of Communications – Bayer U.S. and Head of Communications, Consumer Health North America. Denise will also be a member of the U.S. Corporate Communications Leadership Team, driving reputation, digital excellence and integrated communications.

“Over the last two years, Denise has elevated and brought new relevance to Bayer Consumer Health North America’s largest brands that have been around for decades through integrated marketing, including impactful influencer and social media programs, to truly deliver exceptional results,” Roden said. “We are thrilled she is now officially a member of the Bayer Communications team and will continue to drive our successful integrated communications that has been an essential part of reaching our consumers and driving awareness of our brands.”

Vitola has over a decade and a half of award-winning, branding and integrated marketing experience. She has a broad background working on clients in consumer, health, tech and financial services. Prior to working with Bayer Consumer Health North America, Vitola helped drive innovation and strategy through integrated, social and holistic marketing campaigns for global brands. Earlier this year, Vitola was named a 2021 PRNews Top Woman in PR.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Social Media Channels

- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Danielle Goonan
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
danielle.goonan@bayer.com

More News From Bayer

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose....
Back to Newsroom